Eledon Pharmaceuticals Inc Dossier
Qualitative Analysis
Business overview
Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN) is a clinical-stage biotechnology company focused on developing targeted, immune-modulating therapies to protect transplanted organs and cells, prevent rejection, and treat neurodegenerative diseases. The company's primary focus is the CD40L (CD40 Ligand) pathway, a well-validated biological target that plays a central role in immune cell activation. Eledon's lead investigational asset is tegoprubart (formerly AT-1501), a high-affinity, humanized IgG1 monoclonal antibody designed to inhibit CD40L. By blocking this pathway, tegoprubart aims to provide a safer, less toxic alternative to standard-of-care calcineurin inhibitors (such as tacrolimus), which are associated with severe side effects including kidney damage, increased infection risk, and toxicity to transplanted cells. Eledon is actively evaluating tegoprubart across multiple indications, including kidney transplantation, islet cell transplantation for Type 1 Diabetes (T1D), xenotransplantation, and amyotrophic lateral sclerosis (ALS).
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing lead compound tegoprubart (an anti-CD40L antibody) into Phase 3 clinical trials for the prevention of organ rejection in kidney transplant patients, aiming to replace toxic calcineurin inhibitors like tacrolimus.
Expected impact: Establish tegoprubart as a new, safer standard-of-care immunosuppressant that preserves long-term kidney function (eGFR) without the metabolic and cardiovascular toxicities of tacrolimus.
Expanding the therapeutic footprint of tegoprubart to protect transplanted islet cells in Type 1 Diabetes patients and to serve as a cornerstone immunosuppressant in pig-to-human xenotransplantation.
Expected impact: Address severe organ shortages via xenotransplantation and provide a functional cure for Type 1 Diabetes through durable, immune-protected islet replacement.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
High. The collaboration integrates NewcelX's stem-cell-derived beta cell program (NCEL-101) with Eledon's tegoprubart to support durable, immune-protected islet replacement for Type 1 Diabetes.
Terms: Specific financial terms were not disclosed; the partnership leverages Eledon's extensive transplant experience across more than 100 procedures to support a clearer regulatory pathway.
Medium. Testing tegoprubart in combination with the Sernova Cell Pouch in an ongoing Phase I/II clinical trial to protect transplanted cells.
Terms: Collaborative clinical trial where Sernova leads the study.
High. Collaborating on xenotransplantation procedures, utilizing tegoprubart as a cornerstone immunosuppressive regimen in genetically modified pig-to-human kidney transplants.
Terms: Collaborative research and clinical support.